Novogen Limited (ADR)  

(Public, NASDAQ:NVGN)   Watch this stock  
Find more results for NVGN
1.79
+0.03 (1.70%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.74 - 1.90
52 week 1.51 - 6.54
Open 1.85
Vol / Avg. 0.00/31,331.00
Mkt cap 13.56M
P/E     -
Div/yield     -
EPS -1.02
Shares 168.56M
Beta 0.68
Inst. own 0%
Sep 10, 2014
Novogen Ltd at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -7785.26% -8700.00%
Operating margin -7785.27% -8700.00%
EBITD margin - -6600.00%
Return on average assets -132.92% -145.43%
Return on average equity -279.01% -269.02%
Employees 12 -
CDP Score - -

Address

L 1 16-20 Edgeworth David Ave
SYDNEY, NSW 2077
Australia
+61-2-94760344 (Phone)
+61-2-94760388 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. The Company has three segments: Drug Development, Oncology Drug Program, Consumer Business and Wound Healing. Drug Development includes the discovery of new compounds and the early stage screening for bioactivity of such compounds through both in vivo and in vitro testing. Oncology Drug Program involves the development of selected oncology drug candidates, which have indicated bioactivity against cancer cells through clinical trial programs to assess safety and efficacy. Wound Healing is a separate technology based on Beta-1 Glucan to aid in the management of wounds. The Company�s clinical development program run through Novogen�s subsidiaries Marshall Edwards, Inc. (MEI) and Glycotex, Inc. (Glycotex). In October 2013, Novogen Limited acquired a drug technology.

Officers and directors

Graham Edmund Kelly Chief Executive Officer, Managing Director, Executive Director
Age: 64
Bio & Compensation  - Reuters
Mark G. Hinze CPA Chief Financial Officer
Bio & Compensation  - Reuters
Daniel P. Gold Ph.D. President and Chief Executive Officer of Marshall Edwards, Inc.
Age: 60
Bio & Compensation  - Reuters
Andrew Heaton President and Chief Executive Officer of Novogen North America Inc
Bio & Compensation  - Reuters
David Brown Chief Scientific Officer
Bio & Compensation  - Reuters
Craig D. Kearney General Manager - Consumer Business
Bio & Compensation  - Reuters
Justine R. Stehn Ph.D. Director - ATM Program
Bio & Compensation  - Reuters
Thomas M. Zech Chief Financial Officer of MEI Pharma, Inc.
Age: 62
Bio & Compensation  - Reuters
Lionel Mateo Company Secretary
Bio & Compensation  - Reuters
John P. O'Connor III Non-Executive Chairman of the Board
Bio & Compensation  - Reuters